DBV Technologies

📍 Montrouge, France👥 179 employees💰 Last funded Apr 2021
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
3
Total investors
0
Early stage
1
Mid stage
0
Late stage
Founded
Investor geography3 countries
France
1
United States
1
Denmark
1
Investor activity2007–2021 · investors recorded per year
200712008120211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in DBV Technologies?
DBV Technologies has 3 investors on record on gritt.io, 1 mid-stage.
When did DBV Technologies last raise funding?
The most recent investment in DBV Technologies recorded on gritt.io was in April 2021.
What industry is DBV Technologies in?
DBV Technologies operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is DBV Technologies based?
DBV Technologies is headquartered in Montrouge, France.